MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia

Science Translational Medicine

Volumn 5, Issue 203, 2013, Pages

  Cobbold, Mark ^a,b   De La Peña, Hugo ^b   Norris, Andrew ^c   Polefrone, Joy M ^c   Qian, Jie ^c   English, Ann Michelle ^c   Cummings, Kara L ^a   Penny, Sarah ^b   Turner, James E ^b   Cottine, Jennifer ^c   Abelin, Jennifer G ^c   Malaker, Stacy A ^c   Zarling, Angela L ^a   Huang, Hsing Wen ^b   Goodyear, Oliver ^b   Freeman, Sylvie D ^b   Shabanowitz, Jeffrey ^c   Pratt, Guy ^b   Craddock, Charles ^b,d   Williams, Michael E ^a   Hunt, Donald F ^a,c   Engelhard, Victor H ^a   more..

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF VIRGINIA   (United States)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; HLA B7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHOSPHOPEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL MEMORY; IMMUNOSURVEILLANCE; LEUKEMIA; LEUKEMIA CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HUMANS; IMMUNITY; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; PHOSPHOPEPTIDES; T-LYMPHOCYTES;

EID: 84884683734     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006061     Document Type: Article

References (58)

1. H. J. Kolb, Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371-4383 (2008).
2. C. Preudhomme, J. Guilhot, F. E. Nicolini, A. Guerci-Bresler, F. Rigal-Huguet, F. Maloisel, V. Coiteux, M. Gardembas, C. Berthou, A. Vekhoff, D. Rea, E. Jourdan, C. Allard, A. Delmer, P. Rousselot, L. Legros, M. Berger, S. Corm, G. Etienne, C. Roche-Lestienne, V. Eclache, F. X. Mahon, F. Guilhot; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N. Engl. J. Med. 363, 2511-2521 (2010).
3. M. Talpaz, H. M. Kantarjian, K.McCredie, J.M. Trujillo,M. J. Keating, J. U. Gutterman, Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. N. Engl. J. Med. 314, 1065-1069 (1986).
4. M.M.Horowitz, R. P. Gale, P.M. Sondel, J.M. Goldman, J. Kersey,H. J. Kolb, A. A. Rimm,O. Ringdén, C. Rozman, B. Speck, R. L. Truitt, F. E. Zwaan, M. M. Bortin, Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990).
5. H. J. Kolb, J. Mittermüller, C. Clemm, E. Holler, G. Ledderose, G. Brehm, M. Heim, W. Wilmanns, Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462-2465 (1990).
6. F. Baron, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. Sorror, R. Diaconescu, A. E. Woolfrey, T. R. Chauncey, M. E. Flowers, M. Mielcarek, D. G. Maloney, R. Storb, Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J. Clin. Oncol. 23, 1993-2003 (2005).
7. S. A. Rosenberg, P. Spiess, R. Lafreniere, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321 (1986).
8. P. W. Kantoff, C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, Y. Xu, M. W. Frohlich, P. F. Schellhammer; IMPACT Study Investigators, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
9. S. A. Rosenberg, M. E. Dudley, Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233-240 (2009).
10. S. A. Rosenberg, J. C. Yang, N. P. Restifo, Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
11. W. K. Hong, R. C. Bast Jr., W. Hait, D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, J. F. Holland, E. Frei III, Holland-Frei Cancer Medicine (McGraw-Hill Medical, New York, 2009).
12. K. R. Chi, Cancer research: Promise of protection. Nature 471, 537- 538 (2011).
13. T. J. Ley, E. R.Mardis, L. Ding, B. Fulton, M. D. McLellan, K. Chen, D. Dooling, B. H. Dunford-Shore, S. McGrath, M. Hickenbotham, L. Cook, R. Abbott, D. E. Larson, D. C. Koboldt, C. Pohl, S. Smith, A. Hawkins, S. Abbott, D. Locke, L.W. Hillier, T. Miner, L. Fulton, V. Magrini, T. Wylie, J. Glasscock, J. Conyers, N. Sander, X. Shi, J. R. Osborne, P. Minx, D. Gordon, A. Chinwalla, Y. Zhao, R. E. Ries, J. E. Payton, P. Westervelt, M. H. Tomasson, M. Watson, J. Baty, J. Ivanovich, S. Heath, W. D. Shannon, R. Nagarajan, M. J. Walter, D. C. Link, T. A. Graubert, J. F. DiPersio, R. K. Wilson, DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
14. S. Jones, X. Zhang, D. W. Parsons, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, S. M. Hong, B. Fu, M. T. Lin, E. S. Calhoun, M. Kamiyama, K. Walter, T. Nikolskaya, Y. Nikolsky, J. Hartigan, D. R. Smith, M. Hidalgo, S. D. Leach, A. P. Klein, E. M. Jaffee, M. Goggins, A. Maitra, C. Iacobuzio-Donahue, J. R. Eshleman, S. E. Kern, R. H. Hruban, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, K. W. Kinzler, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
15. D. W. Parsons, M. Li, X. Zhang, S. Jones, R. J. Leary, J. C. Lin, S. M. Boca, H. Carter, J. Samayoa, C. Bettegowda, G. L. Gallia, G. I. Jallo, Z. A. Binder, Y. Nikolsky, J. Hartigan, D. R. Smith, D. S. Gerhard, D. W. Fults, S. VandenBerg, M. S. Berger, S. K. Marie, S. M. Shinjo, C. Clara, P. C. Phillips, J. E. Minturn, J. A. Biegel, A. R. Judkins, A. C. Resnick, P. B. Storm, T. Curran, Y. He, B. A. Rasheed, H. S. Friedman, S. T. Keir, R. McLendon, P. A. Northcott, M. D. Taylor, P. C. Burger, G. J. Riggins, R. Karchin, G. Parmigiani, D. D. Bigner, H. Yan, N. Papadopoulos, B. Vogelstein, K.W. Kinzler, V. E. Velculescu, The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435-439 (2011).
16. D. R. van, W. H. Zoutman, R. Dijkman, R. X. de Menezes, S. Commandeur, A. A. Mulder, P. A. van der Velden, M. H. Vermeer, R.Willemze, P. S. Yan, T. H. Huang, C. P. Tensen, Epigenetic profiling of cutaneous T-cell lymphoma: Promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J. Clin. Oncol. 23, 3886-3896 (2005).
17. E. Tiacci, V. Trifonov, G. Schiavoni, A. Holmes, W. Kern, M. P. Martelli, A. Pucciarini, B. Bigerna, R. Pacini, V. A. Wells, P. Sportoletti, V. Pettirossi, R. Mannucci, O. Elliott, A. Liso, A. Ambrosetti, A. Pulsoni, F. Forconi, L. Trentin, G. Semenzato, G. Inghirami, M. Capponi, R. F. Di, C. Patti, L. Arcaini, P. Musto, S. Pileri, C. Haferlach, S. Schnittger, G. Pizzolo, R. Foà, L. Farinelli, T. Haferlach, L. Pasqualucci, R. Rabadan, B. Falini, BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
18. B. J. Druker, F. Guilhot, S. G. O'brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. W. Deininger, R. T. Silver, J. M. Goldman, R. M. Stone, F. Cervantes, A. Hochhaus, B. L. Powell, J. L. Gabrilove, P. Rousselot, J. Reiffers, J. J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. L. Nielsen, J. P. Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, R. A. Larson; IRIS Investigators, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
19. C. Harrison, Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nat. Rev. Drug Discov. 11, 96 (2012).
20. A. Pardanani, J. R. Gotlib, C. Jamieson, J. E. Cortes, M. Talpaz, R. M. Stone, M. H. Silverman, D. G. Gilliland, J. Shorr, A. Tefferi, Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol. 29, 789-796 (2011).
21. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
22. A. L. Zarling, J. M. Polefrone, A. M. Evans, L. M. Mikesh, J. Shabanowitz, S. T. Lewis, V. H. Engelhard, D. F. Hunt, Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 103, 14889-14894 (2006).
23. A. L. Zarling, S. B. Ficarro, F. M. White, J. Shabanowitz, D. F. Hunt, V. H. Engelhard, Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J. Exp. Med. 192, 1755-1762 (2000).
24. F. R. Depontieu, J. Qian, A. L. Zarling, T. L. McMiller, T. M. Salay, A. Norris, A. M. English, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, S. L. Topalian, Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 106, 12073-12078 (2009).
25. K. T. Hogan, D. P. Eisinger, S. B. Cupp III, K. J. Lekstrom, D. D. Deacon, J. Shabanowitz, D. F. Hunt, V. H. Engelhard, C. L. Slingluff Jr., M. M. Ross, The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res. 58, 5144-5150 (1998).
26. V. S. Meyer, O. Drews, M. Günder, J. Hennenlotter, H. G. Rammensee, S. Stevanovic, Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J. Proteome Res. 8, 3666 -3674 (2009).
27. F. Mohammed, M. Cobbold, A. L. Zarling, M. Salim, G. A. Barrett-Wilt, J. Shabanowitz, D. F. Hunt, V. H. Engelhard, B. E. Willcox, Phosphorylation- dependent interaction between antigenic peptides and MHC class I: A molecular basis for the presentation of transformed self. Nat. Immunol. 9, 1236-1243 (2008).
28. J. E. Beaver, P. E. Bourne, J. V. Ponomarenko, EpitopeViewer: A Java application for the visualization and analysis of immune epitopes in the Immune Epitope Database and Analysis Resource (IEDB). Immunome Res. 3, 3 (2007).
29. P. V. Hornbeck, I. Chabra, J. M. Kornhauser, E. Skrzypek, B. Zhang, PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 4, 1551-1561 (2004).
30. T. Marafioti, C. Mancini, S. Ascani, E. Sabattini, P. L. Zinzani, M. Pozzobon, K. Pulford, B. Falini, E. S. Jaffe, H. K. Müller-Hermelink, D. Y. Mason, S. A. Pileri, Leukocyte-specific phosphoprotein-1 and PU.1: Two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocytepredominant Hodgkin's disease. Haematologica 89, 957-964 (2004).
31. D. Hamann, P. A. Baars, M. H. Rep, B. Hooibrink, S. R. Kerkhof-Garde, M. R. Klein, R. A. van Lier, Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186, 1407-1418 (1997).
32. R. H. Schwartz, T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003).
33. E. Girbal-Neuhauser, J. J. Durieux, M. Arnaud, P. Dalbon, M. Sebbag, C. Vincent, M. Simon, T. Senshu, C.Masson-Bessière, C. Jolivet-Reynaud, M. Jolivet, G. Serre, The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J. Immunol. 162, 585-594 (1999).
34. H. Arentz-Hansen, R. Körner, O. Molberg, H. Quarsten, W. Vader, Y. M. Kooy, K. E. Lundin, F. Koning, P. Roepstorff, L. M. Sollid, S. N. McAdam, The intestinal T cell response to a-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J. Exp. Med. 191, 603-612 (2000).
35. D. M. Wuttge, M. Bruzelius, S. Stemme, T-cell recognition of lipid peroxidation products breaks tolerance to self proteins. Immunology 98, 273 -279 (1999).
36. P. J. Utz, M. Hottelet, P. H. Schur, P. Anderson, Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J. Exp. Med. 185, 843-854 (1997).
37. M. J. Mamula, R. J. Gee, J. I. Elliott, A. Sette, S. Southwood, P. J. Jones, P. R. Blier, Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins. J. Biol. Chem. 274, 22321-22327 (1999).
38. M. J. Scanlan, A. O. Gure, A. A. Jungbluth, L. J. Old, Y. T. Chen, Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22-32 (2002).
39. T. Okada, M. Akada, T. Fujita, T. Iwata, Y. Goto, K. Kido, T. Okada, Y. Matsuzaki, K. Kobayashi, S. Matsuno, M. Sunamura, Y. Kawakami, A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers. Clin. Cancer Res. 12, 191-197 (2006).
40. S. A. Rosenberg, D. E. White, Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19, 81-84 (1996).
41. P. R. Dunbar, J. L. Chen, D. Chao, N. Rust, H. Teisserenc, G. S. Ogg, P. Romero, P. Weynants, V. Cerundolo, Cutting edge: Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J. Immunol. 162, 6959-6962 (1999).
42. C. E. Touloukian, W. W. Leitner, R. E. Schnur, P. F. Robbins, Y. Li, S. Southwood, A. Sette, S. A. Rosenberg, N. P. Restifo, Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J. Immunol. 170, 1579-1585 (2003).
43. T. A. Colella, T. N. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, V. H. Engelhard, Self-tolerance to the murine homologue of a tyrosinasederived melanoma antigen: Implications for tumor immunotherapy. J. Exp. Med. 191, 1221-1232 (2000).
44. S. Gottschalk, C. M. Rooney, H. E. Heslop, Post-transplant lymphoproliferative disorders. Annu. Rev. Med. 56, 29-44 (2005).
45. + T-cell clones recognizing human lymphoma-associated antigens: Generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells. Blood 114, 807-815 (2009).
46. S. Bose, M. Deininger, J. Gora-Tybor, J. M. Goldman, J. V. Melo, The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. Blood 92, 3362-3367 (1998).
47. W. G. Nieto, J. Almeida, A. Romero, C. Teodosio, A. López, A. F. Henriques, M. L. Sánchez, M. Jara-Acevedo, A. Rasillo, M. González, P. Fernández-Navarro, T. Vega, A. Orfao; Primary Health Care Group of Salamanca for the Study of MBL, Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood 114, 33 -37 (2009).
48. A. C. Rawstron, F. L. Bennett, S. J. O 'Connor, M. Kwok, J. A. Fenton, M. Plummer, T. R. de, R. G. Owen, S. J. Richards, A. S. Jack, P. Hillmen, Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N. Engl. J. Med. 359, 575-583 (2008).
49. J. M. den Haan, L. M. Meadows, W. Wang, J. Pool, E. Blokland, T. L. Bishop, C. Reinhardus, J. Shabanowitz, R. Offringa, D. F. Hunt, V. H. Engelhard, E. Goulmy, The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism. Science 279, 1054-1057 (1998).
50. + minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl. Acad. Sci. U.S.A. 96, 8639-8644 (1999).
51. A. G. Brickner, E. H. Warren, J. A. Caldwell, Y. Akatsuka, T. N. Golovina, A. L. Zarling, J. Shabanowitz, L. C. Eisenlohr, D. F. Hunt, V. H. Engelhard, S. R. Riddell, The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J. Exp. Med. 193, 195-206 (2001).
52. S. Z. Pavletic, G. Zhou, K. Sobocinski, G. Marti, K. Doney, J. DiPersio, W. Feremans, L. Foroni, S. Goodman, G. Prentice, C. LeMaistre, G. Bandini, A. Ferrant, N. Jacobsen, I. Khouri, R. P. Gale, A. Wiestner, S. Giralt, E. Montserrat, W. C. Chan, C. Bredeson; Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, Genetically identical twin transplantation for chronic lymphocytic leukemia. Leukemia 21, 2452-2455 (2007).
53. R. P. Gale, M. M. Horowitz, R. C. Ash, R. E. Champlin, J. M. Goldman, A. A. Rimm, O. Ringdén, J. A. Stone, M. M. Bortin, Identical-twin bone marrow transplants for leukemia. Ann. Intern. Med. 120, 646 -652 (1994).
54. N. Kröger, R. Brand, B. A. van, D. Bron, D. Blaise, E. Hellström-Lindberg, G. Gahrton, R. Powles, T. Littlewood, B. Chapuis, A. Zander, V. Koza, D. Niederwieser, W. T. de Witte; Myelodysplastic Syndromes Subcommittee of the Chronic Leukaemia Working Party, European Blood and Marrow Transplantation Group, Stem cell transplantation from identical twins in patients with myelodysplastic syndromes. Bone Marrow Transplant. 35, 37-43 (2005).
55. E. Ozdemir, R. M. Saliba, R. E. Champlin, D. R. Couriel, S. A. Giralt, L. M. de, I. F. Khouri, C. Hosing, S. M. Kornblau, P. Anderlini, E. J. Shpall, M. H. Qazilbash, J. J. Molldrem, R. F. Chemaly, K. V. Komanduri, Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 40, 125- 136 (2007).
56. J. E. Syka, J. J. Coon, M. J. Schroeder, J. Shabanowitz, D. F. Hunt, Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 101, 9528-9533 (2004).
57. M. Cobbold, N. Khan, B. Pourgheysari, S. Tauro, D. McDonald, H. Osman, M. Assenmacher, L. Billingham, C. Steward, C. Crawley, E. Olavarria, J. Goldman, R. Chakraverty, P. Mahendra, C. Craddock, P. A. Moss, Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202, 379-386 (2005).
58. + T-cell clones for immunotherapy from the na¿ve repertoire. J. Immunol. Methods 310, 40-52 (2006).